The model was not sensitive to any inputs within the proposed ranges. Using probabilistic sensitivity analysis, US and cystoscopy was the dominant strategy in 100% of simulations.
INTRODUCTION AND OBJECTIVES:
In 2012, the American Urological Association released updated guidelines for asymptomatic microhematuria management that required only a single positive microscopic urinalysis, as opposed to requiring a confirmatory urinalysis. This change was motivated by questions regarding the validity of a confirmatory urinalysis and literature supporting only a single urinalysis. The cost effectiveness of this new guideline was not considered.
METHODS: We used a decision tree model to compare an immediate microhematuria evaluation based on a single positive urinalysis (Upfront) versus a delayed evaluation requiring a confirmatory positive urinalysis (Confirmed). Cancer detection rates were estimated from studies on asymptomatic microhematuria. Costs were based on national Medicare reimbursement. One-way and two-way sensitivity analyses were performed on critical estimated inputs.
RESULTS: The Upfront workup was 66% more costly than Confirmed ($776 vs. $466/patient), while gaining 0.03 life-years, for an incremental cost effectiveness ratio of $10,719/life-year gained. However, the analysis was sensitive to variation of 2 uncertain parameters: the probability of a delayed cancer diagnosis with the Confirmed strategy (base case value 1.67%) and loss of life expectancy with a delayed diagnosis (base case 1.11 year). When simultaneously varying them in a 2-way sensitivity analysis (Figure) with a $100,000/life-year threshold, Upfront is favored unless the probability of delayed diagnosis with in Confirmed was < 0.15% or if loss in life expectancy with delay was < 0.15 years.
CONCLUSIONS: From a cost effectiveness standpoint, a confirmed positive urinalysis is favored if there is a low likelihood of delayed cancer detection or if there is a minimal loss in life expectancy from a delayed diagnosis. More definitive evaluation of the cost effectiveness of asymptomatic microhematuria guidelines will require a better estimation of these unknown parameters.
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PD14-12 COMPARISON OF INITIAL AND FOLLOW-UP HOSPITAL COSTS FOR MINIMALLY INVASIVE VS. OPEN RADICAL CYSTECTOMY IN A NATIONALLY REPRESENTATIVE SAMPLE
Meera Chappidi*, Max Kates, Trinity Bivalacqua, Phillip Pierorazio, Baltimore, MD INTRODUCTION AND OBJECTIVES: Previous studies demonstrated higher initial hospitalization and 90-day hospital costs for minimally-invasive (MIRC) vs. open radical cystectomy (ORC). These studies were limited in that they were conducted with Medicare databases (>65 years-old) or private payer databases (<65 years-old). Therefore, our objective was to compare initial, 30-day, and 90-day follow-up hospital costs for patients undergoing MIRC vs. ORC in a nationally representative sample containing both Medicare and nonMedicare beneficiaries.
METHODS: We queried the 2013 Nationwide Readmissions Database for bladder cancer patients undergoing RC. ICD-9 codes were used to determine surgical approach. Initial, 30-day, and 90-day hospital costs, length of stay (LOS), and complication rates were compared between MIRC and ORC patients. Multivariable linear regression was performed to determine if surgical approach was a significant predictor of 30-day and 90-day hospital costs after controlling Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e281
